Clinical Trials Logo

Clinical Trial Summary

A phase 1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, antigen-specific immune response and preliminary antitumor activity associated with VB10.NEO administered in combination with atezolizumab, and to identify a RP2D for VB10.NEO in combination with atezolizumab, in patients with locally advanced and metastatic tumors that have progressed after at least 1 available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable, or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized standard of care (SOC).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05018273
Study type Interventional
Source Nykode Therapeutics ASA
Contact
Status Active, not recruiting
Phase Phase 1
Start date December 21, 2021
Completion date December 2024

See also
  Status Clinical Trial Phase
Recruiting NCT06404528 - Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours N/A
Terminated NCT04467853 - A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors Phase 1
Terminated NCT05698888 - Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors Phase 1
Recruiting NCT04587479 - A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors Phase 1
Withdrawn NCT05472220 - Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma Phase 1
Recruiting NCT05354323 - NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors Phase 1
Recruiting NCT05430373 - GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors Phase 1
Recruiting NCT04739293 - Study of ON 123300 in Patients With Advanced Cancer Phase 1
Not yet recruiting NCT05747339 - A Clinical Study on the Efficacy and Mechanism of Tumor Treatment Vaccine (TTV) for Recurrent and Refractory Advanced Solid Tumors N/A
Recruiting NCT05887492 - Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05228015 - Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors Phase 1
Recruiting NCT04621435 - Imaging of Solid Tumors Using FAP-2286 Phase 1
Recruiting NCT05861895 - A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors Phase 1
Recruiting NCT06088472 - TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors Early Phase 1
Recruiting NCT05768139 - First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors Phase 1/Phase 2